Potent and nontoxic antisense oligonucleotides containing locked nucleic acids

Area of Science:

• Biochemistry
• Molecular Biology
• Oligonucleotide Therapeutics

Background:

• Antisense oligonucleotides (ASOs) face limitations in efficacy and specificity for in vivo applications.
• Current ASO designs often exhibit susceptibility to degradation and potential toxicity.
• Developing more stable and effective ASO analogs is crucial for advancing gene silencing therapies.

Purpose of the Study:

• To evaluate the potential of locked nucleic acid (LNA) as a DNA analog for enhancing antisense agent properties.
• To assess the stability, mechanism of action, and in vivo performance of LNA/DNA copolymers.
• To investigate the safety profile of LNA-based antisense agents.

Main Methods:

• Synthesis and characterization of LNA/DNA copolymers.
• Assessment of nuclease resistance in blood serum and cell extracts.
• Evaluation of RNase H activation capability.
• In vivo toxicity studies in rat brain.
• Testing antisense activity using G-protein-coupled receptor and Escherichia coli reporter gene models.

Main Results:

• LNA/DNA copolymers demonstrated significantly improved resistance to degradation compared to DNA.
• The LNA/DNA copolymers effectively activated RNase H, a key mechanism for antisense efficacy.
• Isosequential LNA analogs showed no detectable toxic reactions in rat brain, unlike some phosphorothioate oligonucleotides.
• Potent antisense activity was observed across diverse experimental systems, including in vivo models.

Conclusions:

• Locked nucleic acid (LNA) confers desirable properties, enhancing the in vivo utility of antisense oligonucleotides.
• LNA/DNA copolymers offer a promising platform for developing next-generation antisense therapeutics with improved stability, efficacy, and safety.
• The findings suggest broad applicability of LNA-containing oligonucleotides in various antisense-based therapeutic strategies.